(Q33284961)

25 July 2017

1 reference

title

Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review (English)

1 reference

25 July 2017

Al-Inany HG

1

1 reference

PubMed ID

17509210

25 July 2017

Abou-Setta AM

series ordinal

2

1 reference

PubMed ID

17509210

25 July 2017

Aboulghar M

series ordinal

3

1 reference

25 July 2017

1 May 2007

1 reference

Reproductive BioMedicine Online

25 July 2017

1 reference

25 July 2017

14

1 reference

25 July 2017

5

1 reference

25 July 2017

640-649

1 reference

Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group

25 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961059-0

7 January 2021

Hormonal profile during the follicular phase in cycles stimulated with a combination of human menopausal gonadotrophin and gonadotrophin-releasing hormone antagonist (Cetrorelix).

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961059-0

7 January 2021

A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961059-0

7 January 2021

GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961059-0

7 January 2021

Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961059-0

7 January 2021

Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961059-0

7 January 2021

Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961059-0

7 January 2021

A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961059-0

7 January 2021

The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961059-0

7 January 2021

Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961059-0

7 January 2021

A modified gonadotropin-releasing hormone (GnRH) antagonist protocol failed to increase clinical pregnancy rates in comparison with the long GnRH protocol

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961059-0

7 January 2021

GnRH antagonist in IVF poor-responder patients: results of a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961059-0

7 January 2021

Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961059-0

7 January 2021

Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin).

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961059-0

7 January 2021

The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961059-0

7 January 2021

The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961059-0

7 January 2021

A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist-treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961059-0

7 January 2021

Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961059-0

7 January 2021

A randomised study of GnRH antagonist (cetrorelix) versus agonist (busereline) for controlled ovarian stimulation: effect on safety and efficacy.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961059-0

7 January 2021

A prospective randomized study comparing gonadotropin-releasing hormone agonists or gonadotropin-releasing hormone antagonists in couples with unexplained infertility and/or mild oligozoospermia.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2961059-0

7 January 2021

10.1016/S1472-6483(10)61059-0

Identifiers

DOI

1 reference

25 July 2017

1 reference

PubMed ID

17509210